{"id":"NCT00603473","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures","officialTitle":"An Open-Label, Multicenter Study Evaluating, The Efficacy, Safety And Pharmacokinetics Of Gabapentin As Adjunctive Therapy In Pediatric Patients With Partial Seizures When Other Antiepileptics Do Not Provide Satisfactory Effects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2009-12","completion":"2009-12","firstPosted":"2008-01-29","resultsPosted":"2011-02-21","lastUpdate":"2021-02-03"},"enrollment":92,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsies, Partial"],"interventions":[{"type":"DRUG","name":"gabapentin","otherNames":[]}],"arms":[{"label":"gabapentin","type":"EXPERIMENTAL"}],"summary":"Examine the efficacy, safety and pharmacokinetics of gabapentin as adjunctive therapy in Japanese pediatric patients with partial seizures","primaryOutcome":{"measure":"Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures","timeFrame":"12 weeks","effectByArm":[{"arm":"Gabapentin","deltaMin":-0.158,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":26,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9451162&StudyName=A%20Phase%20III%20Open-Label%20Study%20Of%20Gabapentin%20As%20Adjunctive%20Therapy%20In%20Japanese%20Pediatric%20Patients%20With%20Partial%20Seizures"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":89},"commonTop":["Somnolence","Nasopharyngitis","Influenza","Fall","Diarrhoea"]}}